The 2026 Compounded GLP-1
Landscape: What Changed

The compounded GLP-1 telehealth market looks different in 2026 than it did even a year or two ago, and Henry Meds — like most providers in this space — has adjusted its program accordingly. Here's what's changed at a category level, and what to watch for regardless of which specific provider you're considering.

The Industry-Wide Context

The FDA determined the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. That shift narrowed the legal basis for routine, cost-driven "essentially a copy" compounding across the entire industry — not specific to any one company. In response, providers across the market have adjusted their offerings meaningfully: some discontinued certain compounded products entirely, others shifted toward alternative formats (like oral tablets or sublingual drops) or longer program commitments, and pricing structures have generally become more variable and dose-dependent than the simple flat rates common a couple of years ago.

This industry-wide adjustment period has been genuinely disorienting for patients trying to compare providers, since the market moved from a period of relatively simple, standardized flat-rate compounded pricing to a considerably more fragmented landscape with varying program lengths, format options, and pricing tiers spread across dozens of competing platforms. What was a straightforward comparison in 2023 or 2024 requires meaningfully more diligence in 2026 to evaluate accurately.

The FDA's April 2026 proposal to permanently remove semaglutide, tirzepatide, and liraglutide from the bulk 503B compounding list represents a further regulatory step that, if finalized, would narrow the legal compounding landscape even further beyond the shortage-resolution changes already in effect. Providers who've built compliant, individualized-justification compounding practices are better positioned to weather this additional layer of regulatory tightening than those relying on the looser standards that applied during the active shortage period, when documentation requirements were considerably less stringent across the industry.

What to Verify With Any Provider Right Now

Given how much has shifted across this fast-moving industry, it's worth directly confirming several important things before enrolling or renewing with any compounded GLP-1 provider in 2026: which specific medication format is currently offered (injectable, oral tablet, sublingual), what the current program length and delivery schedule looks like (some programs now bundle multiple months of medication into a single upfront commitment), what the actual all-in monthly cost is at your expected dose, and which licensed pharmacy is preparing your medication.

It's also worth asking directly what documented clinical justification a provider maintains for prescribing compounded rather than brand-name medication, since this is now a required element of legitimate 503A compounding following the shortage resolutions, not an optional formality. A provider unwilling or unable to answer this clearly is worth treating with additional caution, regardless of how competitive their advertised pricing appears.

Independently verifying the specific compounding pharmacy's state license, rather than relying solely on a provider's marketing claims, takes only a few minutes through that state's board of pharmacy website and provides meaningfully more assurance than assuming a "licensed pharmacy" claim is automatically accurate or current given how quickly this market has continued to shift, even for providers with an established reputation and years of prior operation in this space.

Reading the Fine Print on Commitment Terms

Before enrolling in any multi-month program specifically, read the cancellation and refund terms carefully, not just the pricing table on the homepage. Ask directly what specifically happens if you want to stop partway through a 6- or 12-month commitment — whether unused months are refunded, prorated, or simply forfeited entirely without recourse. This single question can meaningfully change the real cost comparison between two providers whose advertised monthly price looks similar on the surface but whose actual commitment flexibility differs considerably from one another once you look closely at the specific terms.

It's also worth asking what happens if a specific medication format becomes unavailable partway through your commitment period, given how much format availability has shifted across the industry recently and unpredictably. A provider with a clear, patient-friendly policy for this scenario (switching you to an equivalent option at the same price, for example) is a meaningfully better bet than one with no stated policy at all, since format changes have become a realistic possibility rather than a hypothetical concern, and patients who signed up for one format have genuinely found themselves switched to another without much advance notice or a clear pricing adjustment.

Weighing Format Changes Honestly

As providers have shifted toward alternative formats like oral tablets and sublingual drops, it's worth understanding that these formats generally have a thinner clinical evidence base than the standard injectable formulation that's been studied extensively in trials like STEP and SURMOUNT. The FDA has specifically raised concerns about compounded oral GLP-1 delivery formats, distinct from the well-established injectable route. If format flexibility matters to you, that's a legitimate preference, but it's worth weighing against the more extensive trial evidence supporting standard injectable dosing specifically.

This isn't to say alternative formats have no place — needle aversion is a real and understandable barrier to treatment for some patients, and a less-studied format that gets someone started on treatment may be preferable to no treatment at all. The point is simply to make this tradeoff consciously and with accurate information, rather than assuming a newer format carries the same weight of clinical evidence as the injectable formulation that's been the primary basis for the efficacy data most patients have heard about through news coverage and word of mouth.

Why Pricing Has Gotten Harder to Compare

Compounded GLP-1 pricing across the market as a whole has become considerably more variable and complex than it was during the shortage era, when flat, dose-independent pricing was common industry-wide. Total monthly costs across providers can now range broadly and unpredictably depending on dose, program length, and whether pricing is flat or tiered by dosage strength. When comparing options, it's worth calculating your actual expected cost at your target maintenance dose over a realistic treatment timeline, rather than comparing advertised starting prices.

A useful exercise is running the math for a full year of treatment at your expected maintenance dose across each provider you're considering, rather than comparing month-one or starting-dose prices, which can differ substantially from what you'll actually pay once you've titrated to an effective, ongoing dose. This kind of comparison takes a bit more effort upfront, but it's the only reliable way to know which option is actually cheaper for your specific treatment course over a full year, rather than which one simply has the most attractive advertised entry price at the lowest dose tier.

What Hasn't Changed

The clinical fundamentals remain exactly the same regardless of which provider or program structure you ultimately choose to go with: eligibility criteria (generally BMI ≥30, or ≥27 with a weight-related condition), the importance of gradual dose titration to manage side effects, and the value of a real medical evaluation before starting treatment. Those fundamentals should remain non-negotiable with any provider you choose, regardless of whatever else has changed around them in the broader industry.

It's also worth remembering that the underlying medications themselves — semaglutide and tirzepatide — haven't changed in efficacy or mechanism through any of these industry shifts. The clinical trial data supporting their use (STEP and SURMOUNT trial programs, among others) remains just as relevant in 2026 as it was before the regulatory landscape shifted, since these trials assessed the active molecules themselves, not any specific company's business model, program structure, or pricing tier arrangement.

What to Prioritize When Comparing Providers

Given how much has shifted across the industry, prioritize transparency about medication format, pricing structure, program commitment terms, and pharmacy licensing over the lowest advertised starting price alone, since that headline number often doesn't reflect the full picture of what you'll actually pay and commit to over a full treatment course. A provider that answers these questions clearly and specifically, without hedging or deflecting, tends to be a more reliable long-term choice than one that leads only with an attractive entry price and leaves the details to be discovered after enrollment has already begun and payment information has been submitted.

Frequently Asked Questions

References

1. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. 2025. FDA.gov
2. U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov
3. GoodRx. The Tirzepatide Shortage Is Over: Here's What You Need to Know. GoodRx.com. 2026. GoodRx.com
4. U.S. Food and Drug Administration. Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide). FDA.gov. 2025. FDA Drug Approvals Database